These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 24481299)

  • 1. Court clears the way for Nexium alternative.
    Harrison C
    Nat Rev Drug Discov; 2014 Feb; 13(2):94. PubMed ID: 24481299
    [No Abstract]   [Full Text] [Related]  

  • 2. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
    Wang Z
    Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
    [No Abstract]   [Full Text] [Related]  

  • 3. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry.
    Ritter M; Tempesta J; Ragusa P
    Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 5. Industry Payments to Physicians and Prescriptions of Brand-Name Proton-Pump Inhibitors.
    Morse E; Fujiwara RJT; Mehra S
    Otolaryngol Head Neck Surg; 2019 Jan; 160(1):70-76. PubMed ID: 30325706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intellectual property. Challenges to India's pharmaceutical patent laws.
    Sampat BN; Shadlen KC; Amin TM
    Science; 2012 Jul; 337(6093):414-5. PubMed ID: 22767892
    [No Abstract]   [Full Text] [Related]  

  • 8. On access and accountability--two Supreme Court rulings on generic drugs.
    Boumil MM; Curfman GD
    N Engl J Med; 2013 Aug; 369(8):696-7. PubMed ID: 23923990
    [No Abstract]   [Full Text] [Related]  

  • 9. Protecting your domain.
    Eagle TE
    Mich Health Hosp; 2002; 38(1):24-6. PubMed ID: 11828575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Federal court raises the bar for overturning patents.
    Schubert C
    Nat Med; 2011 Jul; 17(7):758. PubMed ID: 21738135
    [No Abstract]   [Full Text] [Related]  

  • 11. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
    Teitelbaum R; Cohen M
    Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
    [No Abstract]   [Full Text] [Related]  

  • 12. Unsettling drug patent settlements: a framework for presumptive illegality.
    Carrier MA
    Mich Law Rev; 2009 Oct; 108(1):37-80. PubMed ID: 20535881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
    Lietzan EK
    Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pfizer receives US$2.15 billion in patent damages.
    Sklan A
    Pharm Pat Anal; 2013 Sep; 2(5):583. PubMed ID: 24386655
    [No Abstract]   [Full Text] [Related]  

  • 15. GATT implementation and generic drug approval.
    Safir PO; Lassman SM
    Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmaceuticals and medical devices: business practices. End-of-year issue brief.
    Jones TM
    Issue Brief Health Policy Track Serv; 2010 Jan; ():1-58. PubMed ID: 20213918
    [No Abstract]   [Full Text] [Related]  

  • 17. Patent watch.
    Harrison C
    Nat Rev Drug Discov; 2008 Nov; 7(11):882-3. PubMed ID: 18974746
    [No Abstract]   [Full Text] [Related]  

  • 18. [An analysis of the decision of the Italian Constitutional Court repealing the ban on patents in the pharmaceutical field and of the subsequent provisions].
    Klausner E
    Farmaco Prat; 1980 Aug; 35(8):381-90. PubMed ID: 7449957
    [No Abstract]   [Full Text] [Related]  

  • 19. The extraterritoriality of US patents on the pharmaceutical industry.
    Park H
    Pharm Pat Anal; 2014 Sep; 3(5):491-8. PubMed ID: 25374318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues in the interpretation of 180-day exclusivity.
    Lietzan E; Korn DE
    Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.